Similarly, no differences were observed for SMA + CAFs within tumors at end-stage (p = 0.4, Figure 1E), suggesting that increased CCL2 expression within the microenvironment early in tumor development did not have lasting effects on either macrophage or CAF numbers in end-stage tumors. The gene discussed is SMN1; the disease is neoplasm.